Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganagliflozin proline in type 2 diabetes mellitus with MAFLD
ChiCTR2600121344Phase 4Not yet recruiting
- Sponsor
- Hebei General Hospital
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of ganagliflozin in type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Hebei General Hospital. Primary endpoints: Steatosis of liver and Liver stiffness measurement. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
ganagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on ChiCTR2600121344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121344.